News | November 10, 2025
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
The said inspection concluded with Zero Form 483 observation
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Relmada expects to initiate its Phase 3 program in the first half of 2026
Poviztra is a second brand of Wegovy
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Sumatriptan injection is indicated in adults for the acute treatment of migraine
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Subscribe To Our Newsletter & Stay Updated
